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Abstract
Background: Hepatitis is a common adverse effect of antituberculosis drugs. Silymarin prevented drug-induced
hepatoxicity in animals with anti-oxidative mechanisms but its effect in human has been unknown. We aimed to
evaluate the efficacy of silymarin for preventing antituberculosis-drug induced liver injury (antiTB-DILI) in patients
with tuberculosis.
Methods: A double-blind randomized placebo-controlled trial was performed. Tuberculosis patients were randomly
allocated to receive placebo or silymarin. The outcomes of interests were antiTB-DILI and the maximum liver
enzymes at week 4. Antioxidative enzymes (i.e., superoxide dismutase (SOD), glutathione and malondialdehyde
assays) were assessed. The risks of antiTB-DILI between the two groups were compared. A number need to treat
was estimated.
Results: A total of 55 out of 70 expected numbers of patients were enrolled. There were 1/27 (3.7 %) and 9/28
(32.1 %) patients who developed antiTB-DILI in the silymarin and the placebo groups. Risk reduction was 0.28
(0.10, 0.47), i.e., receiving silymarin was 28 % at lower risk for antiTB-DILI than placebo. This led to prevention of
28 patients from being antiTB-DILI among 100 treated patients. Median (IQR) of ALT levels at week 4 in the placebo
and the silymarin group were 35.0 (15, 415) IU/L and 31.5 (20, 184) IU/L (p = 0.455). The decline of SOD level at week 4
in the silymarin group was less than the placebo group (p < 0.027).
Conclusions: Silymarin reduced the incidence of antiTB-DILI. The benefit of silymarin may be explained from
superoxide dismutase restoration. Larger clinical trials are required to confirm the result of our small study
[Clinicaltrials.Gov Identifier Nct01800487].
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Background
Tuberculosis is one of the leading causes of death
among infectious diseases in developing and undevel-
oped countries [1]. The standard treatment regimen of
antituberculosis drugs during an intensive phase consists
of isoniazid, rifampicin and pyrazinamide. In many
countries, ethambutol is added in the intensive regimen
during the initial two months of treatment to improve
the efficacy of anti-tuberculosis therapy and shorten the
total duration of treatment [2].
Hepatotoxicity, a common adverse effect of anti-
tuberculosis drugs, varies from asymptomatic eleva-
tion of liver enzymes to fulminant hepatic failure.
Antituberculosis-drug induced liver injury (antiTB-
DILI) results in increased morbidity and mortality,
treatment withdrawal, drug interruption, dose reduc-
tion and selection of drug-resistant organisms [3, 4].
The incidence rate of isoniazid-related hepatotoxicity
is 1.6 % when it is given alone and it increases to
2.6 % when rifampicin is added to the treatment
* Correspondence: Abhasnee.sob@mahidol.ac.th
1Division of Gastroenterology and Hepatology, Department of Medicine, Faculty
of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
4Division of Gastroenterology and Hepatology, Department of Medicine,
Faculty of Medicine, Ramathibodi Hospital, 270 Praram 6 Road, Bangkok
10400, Thailand
Full list of author information is available at the end of the article
© 2015 Luangchosiri et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Luangchosiri et al. BMC Complementary and Alternative Medicine  (2015) 15:334 
DOI 10.1186/s12906-015-0861-7
regimen [5]. Pyrazinamide is a potential hepatotoxic
drug which can cause dose-related hepatotoxicity [6].
Risks and the severity of liver injury go up when pyrazina-
mide, isoniazid and rifampicin are given in combination in
the standard regimen [7–9]. The incidence rates of anti-
TB-DILI reported in the standard treatment regimens vary
from 19.9 % to 27.7 % during the first two months of
treatments [10, 11].
The exact mechanism of liver injury relating to antitu-
berculosis drugs is still unknown. Drug-induced liver
injury from isoniazid and pyrazinamide may share simi-
lar mechanisms, i.e. through the pathways of escalating
oxidative stress and increased oxygen free radical
regeneration [12–14]. Previous studies have reported
that some drugs and herbal medicine, such as garlic
or N-acetylcysteine, can prevent and reduce hepato-
toxicity from antituberculosis drugs [12, 15, 16].
Silymarin, a traditional herbal drug extracted from
milk thistle (Silybum marinums) seeds, has been used as
a supplement remedy for hepatoprotection [17, 18]. The
main components of silymarin comprise silybin, silydia-
nin, silychrisin and isosilybin [17, 19]. All of these are
derivatives of flavonols [17, 19]. Silymarin facilitates
hepatoprotection through scavenging of free radicals,
thereby reducing oxidative stress, restoring the function
of antioxidative enxymes and generating cell membrane
stabilization [17, 18, 20, 21]. From previous studies in an
experimental animal model of anti-tuberculosis related
DILI, it demonstrated that silymarin has a significant
hepatoprotective effect [22, 23].
However, there has never been report of the benefit of
silymarin for the prevention of antiTB-DILI in human.
From a randomized controlled trial of silymarin in acute
hepatitis, it showed that silymarin may be effective in
improving symptoms of acute hepatitis and jaundice
[24]. To date, silymarin has a high safety profile which
has been confirmed from a large number of studies [24].
So far, serious adverse effects of silymarin have not been
reported in both animals and human. We therefore
aimed to assess the efficacy of silymarin in reducing
hepatotoxicity related to the treatment of a standard
combined regimen of antituberculosis drugs.
Methods
Patients
Patients who met the following criteria were enrolled to
the study: those diagnosed with pulmonary tuberculosis
from positive acid-fast staining of sputum and/or typical
pulmonary tuberculosis findings from chest x-ray films,
aged over 18 years, planned to receive a standard anti-
tuberculosis treatment regimen with isoniazid (5 mg/kg/
day), rifampicin (10 mg/kg/day), pyrazinamide (25 mg/
kg/day) and ethambutol (15 mg/kg/day) in the first two
months, and were willing to participate with the study
and gave written consent forms. Exclusion criteria
included active liver diseases (chronic viral hepatitis,
autoimmune hepatitis, alcoholic hepatitis, Wilson’s dis-
ease, hemochromatosis, or cirrhosis), acquired immune
deficiency syndrome, concurrently taking of herbal
medicine, significant alcohol consumption (more than
20 g/day), pregnant or lactating women. In addition,
patients with elevated serum alanine aminotransfer-
ase enzyme (ALT) (more than 2 times of upper
normal limit) prior to enrollment were excluded
from the study.
Study design
A double-blinded randomized controlled trial was
performed between January 2012 and December 2012 at
Faculty of Medicine Ramathibodi Hospital, Mahidol
University, Bangkok, Thailand. The study protocol was
approved by the Committee on Human Rights Related
to Research Involving Human Subjects and it was
carried out according to the Good Clinical Practice
Guideline. Written informed consents were obtained
before enrollment. This study followed the CONSORT
guidelines for randomized controlled trial and the
study protocol was registered at www.clinicaltrials.gov
(NCT01800487).
Randomization and blinding methods
A computerized-based randomization with a block of
two and four was performed by a statistician who was
not involved in recruitment of patients. The randomization
list was then sealed in an opaque envelope. Once patients
met the inclusion criteria, a research assistant opened
envelops and treatments were assigned to patients ac-
cordingly. Patients, research assistants, and doctors did
not know the details of the study drugs that the pa-
tients received.
Treatment protocol
Patients with newly-diagnosed pulmonary tubercu-
losis were referred from pulmonary and infectious
clinics. Anti-tuberculosis drugs were started with the
dosages that were calculated according to patient’s
body weight. Subjects were randomly assigned to
receive either silymarin or placebo (with similar
appearance with the study drug) in concealed allo-
cation manners on the first day of antituberculosis
treatment.
The protocol was carried out in a double-blinded
fashion. One tablet of silymarin (140 mg) or placebo
was taken three times a day along with antitubercu-
losis drugs. Study subjects were emphasized to make
records when taking anti-tuberculosis and the study
drugs. The remaining pills were counted on the days
of follow-up to check patient compliance and adherence.
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Adverse effects were recorded. Alcohol, herbal, and over-
the-counter drugs were prohibited throughout the study
period. Patients were followed up for clinical and liver en-
zyme assessment at week 2 and 4 after the beginning of
the study.
Outcome of interests
The efficacy of silymarin was compared with placebo for
two purposes. The primary outcome of the study was to
determine the maximum ALT level within 4 weeks after
treatment. (Timing of week 4 was chosen because, from
our observation in a pilot study, AST and ALT started to
rise at week 4, not week 8. Moreover, it was not ethical
to continue the study to week 8 or after if the rising of
liver enzymes already occurred at week 4) The secondary
outcome of interest was the development of antiTB-
DILI, which was defined as presence of the following
criteria: 1) having at least one of the following events: an
elevation of serum ALT level more than 2 times above
upper normal limit, a rise in serum total bilirubin level
to more than 1.5 mg/dl, or any increase in ALT level
above baseline levels combined with anorexia, nausea,
vomiting, or jaundice, 2) no other explainable causes of
elevation of liver enzymes, and 3) normalization of liver en-
zymes after withdrawal of antituberculosis drugs [25, 26].
Severity of antiTB-DILI was classified based on World
Health Organization (WHO) guideline as follow: grade 0
for ALT level <1.25 times normal; grade 1 for ALT level
1.25 to 2.5 times normal; grade 2 for ALT level 2.6 to 5.0
times normal; grade 3 for ALT level 5.1 to 10.0 times
normal; grade 4 for ALT level >10 times normal, or
ALT >250 IU/L if accompanied by symptoms (e.g., nau-
sea, vomiting, abdominal pain, jaundice) [27, 28]. The
treatment regimen was terminated after patients developed
antiTB-DILI, whereas the antituberculosis regimen was
modified according to the patient condition.
In addition, antioxidative enzymes (AOE) were also
assessed at baseline and at week 4 after the initiation
of antituberculosis drugs, including superoxide dis-
mutase (SOD) activity, glutathione level and malon-
dialdehyde (MDA) activity. SOD activity in plasma
was estimated by using Superoxide Dismutase activity
assay Kit (BioVision, CA USA). SOD Activity Assay
Standard Curve between percent inhibition and SOD
standard units was used to determine SOD activity.
Glutathione was measured by fluorometric method
using Glutathione assay Kit (BioVision, CA USA).
Malondialdehyde (MDA), a by-product representing
the level of lipid peroxidation, was measured by using
the Lipid peroxidation (MDA) Assay Kit (BioVision,
CA USA. The reactions of SOD, glutathione level and
MDA activity were measured by Infinite® 200 PRO
microplate reader (Tecan, Switzerland).
Finally, adverse events (i.e., decreased appetite, fatigue,
confusion etc.) were reviewed from direct questioning
and self-recording on the follow-up days.
Statistical analysis
Sample size was calculated based on comparing mean
serum ALT between silymarin and placebo. The
previous study reported mean serum ALT after receiv-
ing anti-TB drugs treatment of 463 (SD = 69) IU/L
[11]. We assumed that silymarin works well if it
should be able to decrease serum ALT level at least
10 %. A total of 70 subjects (35 for each treatment
group) were required to detect the difference, given
type I error of 5 % and power of test of 80 %. Taking
into account for the loss of follow up 10 %, a total of
80 subjects were therefore required.
Data were analyzed based on intention to treat analysis
approach. Baseline characteristics were described using
mean or median where appropriate for continuous data
and frequency for categorical data. Student’s t-test was
used to compare mean between treatment groups if data
were normally distributed, otherwise Wilcoxon sum rank
test or a quantile regression was applied to compare
medians between groups. A risk ratio (RR) of having
antiTB-DILI between treatment groups along with its
95 % confidence interval (CI) was estimated. A risk
difference and a number needed to treat were also
estimated. All analyses were performed using STATA
version 13.1. P-value of less than 0.05 was considered
statistical significance.
Results
Due to slow accrual, the recruitment was terminated
prematurely after 68 patients were screened. Ten
patients were excluded due to not meeting inclusion and
exclusion criteria (8 patients) and decline to participate
(2 patients). Fifty-eight patients were enrolled to the
study (Fig. 1), 3 patients (2 in the placebo and 1 in the
silymarin group) were excluded after randomization due
to unwillingness to participate in 1 patient and missed
diagnosis for tuberculosis in 2 patients. Of 55 patients,
27 and 28 patients were randomly assigned to receive
silymarin or placebo, respectively. The trial was termi-
nated and enrollment was stopped due to the limita-
tion of the study duration and safety issues. Baseline
characteristics were not statistically significant differ-
ent between groups except for direct bilirubin, which
was a little higher in the placebo than in the sily-
marin groups (Table 1).
Liver enzymes at week 4 after the initiation of treat-
ment are shown in Table 2. Median (interquartile
range, IQR) of ALT levels in the silymarin and
placebo groups were 32 (20, 184) and 35 (15, 415)
IU/L, which were not significantly different (p = 0.455).
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The incidences of antiTB-DILI at week 4 were 3.7 % and
32.1 % in the silymarin and placebo groups (Table 3).
Patients who received silymarin were approximately 28 %
(95 % CI: 10 %, 47 %) at significantly lower risk of having
antiTB-DILI than placebo. An estimated number need to
treat (NNT) was 3.5 (95 % CI: 2.11, 2.37), which could be
interpreted that one patient can be prevent from antiTB-
DILI in every 4 patients who have been treated with sily-
marin. Similarly, according to the WHO criteria for grading
of DILI, the number of the patients who developed
Fig. 1 Protocol flow chart. New patients with pulmonary tuberculosis were assessed for protocol eligibility
Table 1 Baseline characteristics of patients in placebo and silymarin groups
Silymarin Placebo p-value
(N = 27) (N = 28)
Male (n, %) 10 (37.0) 12 (42.9) 0.785
Age (years) 56.0 (15, 78) 51.5 (21, 83) 0.721
BMI (kg/m2) 21.1 (14.1, 25.4) 21.0 (15.8, 27.0) 0.773
Dose of Isoniazid (mg/kg) 5.5 (4.0, 9.0) 5.7 (4.5, 7.7) 0.968
Dose of rifampicin (mg/kg) 10.4 (8.0, 14.0) 10.3 (9.0, 14.0) 0.965
Dose of pyrazinamide (mg/kg) 23.1 (18.6, 29.1) 23.8 (17.8, 58.0) 0.282
Dose of ethambutol (mg/kg) 18.5 (13.3, 24.9) 18.5 (12.7, 27.8) 0.859
Liver function tests
ALT (IU/L) 29 (15, 66) 31 (11, 86) 0.639
AST (IU/L) 20 (13, 106) 25.5 (14, 56) 0.087
ALP (IU/L) 85 (37, 449) 89.5 (55, 508) 0.736
GGT (IU/L) 42 (17, 430) 52.5 (14, 510) 0.443
TP (g/L) 78.1 (50.5, 91.5) 76.0 (56.1, 99.4) 0.452
Alb (g/L) 35.7 (23.0, 42.0) 33.0 (16.7, 43.8) 0.639
TB (mg/dl) 0.5 (0.3, 1.9) 0.6 (0.2, 1.4) 0.285
DB (mg/dl) 0.2 (0.1, 0.7) 0.3 (0.1, 5.0) 0.015
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; TP, total protein;
Alb, albumin; TB, total bilirubin; DB, direct bilirubin
Categorical variables reported as N (%). Continuous variables reported as median (interquartile range)
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antiTB-DILI was significantly lower in the silymarin
group than in the placebo group [2 (7.4 %) vs. 9
(32.1 %), p = 0.039]. Two patients in the silymarin and
seven patients in the placebo groups developed WHO
grade I-II DILI. Two patients in the placebo group
developed WHO grade III DILI. None of the patients
developed WHO grade IV DILI.
The changing of antioxidative enzymes levels (ΔAOE)
after 4 weeks of treatment (AOE at week 4 – AOE at
baseline) was described in Table 4. Although the median
change of serum transaminase, glutathione and MDA
were not significantly different between the two treat-
ment groups, the decline of mean SOD level at week 4
in the silymarin group was less than in the placebo
group (p =0.027). Serious adverse effects relate to antitu-
berculosis drugs and silymarin were not seen in this
study. The incidences of mild adverse effects (nausea
and dizziness) were not significantly different between
the two groups (Table 5).
Discussion
Antituberculosis drug-related hepatotoxicity is an im-
portant adverse effect that can occur during the first two
months when three or four antituberculosis drugs are
required to take together. The incidence rate of antiTB-
DILI could reach 27.7 % during the intensive phase of
therapy [11]. However, some drugs might be beneficial in
preventing antituberculosis drug-related hepatotoxicity. In
a recent study of animal models, silymarin was found to
prevent hepatitis from antituberculosis drugs [22]. A re-
cent randomized controlled study of silymarin could not
demonstrate the effect of silymarin in the prevention of
antiTB-DILI [29]. However, the study was an open-label
trial, and vitamin C, which is a non-enzymatic low mo-
lecular weight antioxidant [19], was used in the control
arm [29]. We conducted a double-blinded randomized
controlled trial which aimed to assess the efficacy of sily-
marin in the prevention of antiTB-DILI. Although we
could not recruit tuberculosis patients to the expected
number from sample size calculation due to the limitation
of study period and safety reasons, the study result
showed a benefit of silymarin. The risk of antiTB-DILI in
the patients who were treated with silymarin was approxi-
mately 28 % lower than placebo, i.e., 28 patients will be
prevented from antiTB-DILI among 100 treated patients.
However, the small sample size of subjects in both groups
was a considerable limitation of our study.
The efficacy of silymarin was assessed by comparing
ALT levels and the incidence of antiTB-DILI between
the placebo and the silymarin groups. Because most of
antiTB-DILI in this study started to appear in the first
4 weeks, not 8 weeks as described in previous reports
[30], the liver enzymes at week 4 were selected for the
endpoint analysis in this study. There was no patient
who developed antiTB-DILI after week 4 of treatment.
Although the maximum ALT level during 4 weeks after
initiation of antituberculosis treatments were not differ-
ent between the treatment groups [35 (15–415) vs. 31.5
Table 3 Comparison of risk of antituberculosis-drug induced liver injury (antiTB-DILI) between two treatment groups: Intention-to-treat
approach
Placebo Silymarin p-value RR RD NNT
(N = 28) (N = 27) (95 % CI)
DILI 9 (32.1) 1 (3.7) 0.012 0.12 (0.02, 0.85) 0.28 (0.10, 0.47) 3.50 (2.11, 2.37)
Non-DILI 19 (67.9) 26 (96.3) 1
DILI, drug induced liver injury; RR, risk ratio; RD, risk difference; NNT, number need to treat
Categorical variables reported as N (%)
Table 4 The changing of antioxidative enzymes levels (ΔAOE)
after 4 weeks of treatment (AOE at week 4 - AOE at baseline)
ΔAOE after 4 weeks of treatment
Silymarin Placebo p-value
SODa (%) −0.20 (−4.0, 6.4) −4.41 (−6.0, 1.8) 0.027
Glutathionea (ng/ul) −0.09 (−0.3, 0.0) −011 (−0.2, 0.0) 0.83
MDAa (nmol/L) −0.14 (−13.5, 17.1) −9.74 (−23.8, 6.0) 0.22
AOE, Antioxidative enzymes; SOD, superoxide; MDA, malondialdehyde
aΔAOE reported as median (interquartile range)
Table 2 Comparison of liver function tests at week 4 after
initiation of antituberculosis drugs
Silymarin Placebo p-value
(N = 27) (N = 28)
ALT (IU/L) 32 (20, 184) 35 (15, 415) 0.455
AST (IU/L) 26 (14, 219) 29 (13, 386) 0.888
ALP (IU/L) 78 (37, 409) 85 (56, 249) 0.622
GGT (IU/L) 61 (13, 224) 99 (21, 366) 0.215
TP (g/L) 74.2 (25.1, 90.8) 73.3 (48.7, 93.7) 0.920
Alb (g/L) 33.6 (8, 41) 35.0 (19, 69) 0.565
TB (mg/dl) 0.6 (0.2, 2.2) 0.6 (0.2, 6.5) 0.999
DB (mg/dl) 0.3 (0.1, 1.4) 0.3 (0.1, 5.0) 0.999
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline
phosphatase; GGT, gamma-glutamyl transpeptidase; TP, total protein; Alb,
albumin; TB, total bilirubin; DB, direct bilirubin
Continuous variables reported as median (interquartile range)
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(20–184) IU/L], the risk of antiTB-DILI was significantly
higher in the placebo than in the silymarin group,
according to the study protocol and the WHO criteria.
The result of this study suggested that silymarin
(140 mg) three times a day had its efficacy in the preven-
tion of antiTB-DILI. Drug-induced hepatotoxicity leads
to oxidative stress, lipid peroxidation, the reduction of
phospholipids and protein synthesis as well as glutathi-
one in the liver [23]. The mechanisms of action of
silymarin and silybinin encompass hepatoprotection, an-
tioxidation, antiinflammation, antifibrotic activity, stimu-
lation of protein synthesis and liver regeneration, and
enhancing immuno-modulatory effect as summarized in
Fig. 2 [17, 18, 31]. Silymarin inhibits proinflammatory
cytokines, acts as oxygen free radical scavenger and
potentiates antioxidant capacity of the liver [17, 18, 23,
31]. From the results of this study, the mechanism by
which silymarin is beneficial in the prevention of antiTB-
DILI may be explained from superoxide dismutase restor-
ation. An increase in the nuclear translocation of nuclear
factor erythroid 2-related factor 2 (Nrf2) and decreased
tumor necrosis factor (TNF)-α mRNA expression in the
liver may be a protective effect of silymarin in drug-
induced liver injury [32, 33].
Interestingly enough, although the patients in this
study did not have the risk profiles of antiTB-DILI such as
old age or malnutrition [34], we found a higher incidence
of antiTB-DILI (32.1 %) than previously reported (19.9 -
22.2 %) [34]. This phenomenon may be explained from
the modified criteria for the diagnosis of antiTB-DILI that
was used in this study which lowered ALT levels to only 2
times above upper normal limit. When the diagnosis of
antiTB-DILI was made, antituberculosis drugs and/or
their dosages were modified. Patient conditions and
liver enzymes were followed up until liver enzymes
returned to their baseline levels. No patients developed
fulminant hepatic failure or died in this study. In the
silymarin group, there were mild adverse effects simi-
lar to the placebo group. There was no serious adverse
effect occurring in the study. Silymarin has a safety
profile that can be used in liver diseases. Only minor
adverse effects such as diarrhea, nausea, vomiting and
lightheadedness were reported and required only sup-
portive treatment in some patients.
Conclusions
From this study, it is suggested that silymarin has an
efficacy to prevent liver injury from a standard combined
antituberculosis drugs without significant adverse effects.
Superoxide dismutase restoration may be one of the
mechanisms that can explain the benefit of silymarin in
the prevention of antiTB-DILI. However, larger and
better designed clinical trials are required to confirm the
results of our small and single-center study before
silymarin can be safely recommended to prevent liver
injury from antituberculosis drugs.
Fig. 2 Mechanisms of action of silymarin. The positive effects of silymarin on the liver are originated from hepatoprotection, antioxidation,
antiinflammation, antifibrotic activity, the promotiion of liver regeneration and immunomodulation [17, 18, 31]
Table 5 Adverse events
Placebo Silymarin
(N = 28) (N = 27)
Major adverse events 0 0
Minor adverse events 3 (10.7) 3 (10.7)
• Nausea / vomiting 1 3
• Dizziness 2 0
Total 3 (10.7) 3 (10.7)
Categorical variables reported as N (%)
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